Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: review decision - September 2013 information

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: Appendix A - decision paper presented to the Institute's Guidance Executive (PDF 226 KB)

TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: review proposal - July 2013 information

TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: Appendix A provisional matrix of stakeholders (PDF 42 KB)

TA195 Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: Appendix B proposal paper presented to the Institute's Guidance Executive (PDF 519 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: press release  information

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: final appraisal determination information

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: final appraisal determination (PDF 324 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: response to consultee, commentator and public comments on the Appraisal Consultation Document (ACD) (PDF 552 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: consultee and commentator comments on the ACD

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: additional analysis - supplementary data including a continuation rule as in Roche model (PDF 26 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: manufacturer/sponsor

Abbott (PDF 426 KB)

Bristol-Myers Squibb (PDF 125 KB)

Roche (PDF 23 KB)

Schering-Plough (confidential information, including appendix 3, removed) (PDF 276 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: professional and patient groups

Arthritis Care (PDF 64 KB)

Arthritis and Musculoskeletal Alliance (PDF 124 KB)

Arthritis Research (PDF 38 KB)

British Health Professionals in Rheumatology (PDF 17 KB)

British Society for Rheumatology (PDF 102 KB)

National Rheumatoid Arthritis Society (PDF 121 KB)

National Rheumatoid Arthritis Society - appendix 1 (PDF 63 KB)

Royal College of Nursing (PDF 52 KB)

Royal College of Physicians (PDF 28 KB)

Royal College of Pathologists (PDF 29 KB)

Department of Health (PDF 33 KB)

NHS Quality Improvement Scotland (PDF 66 KB)

UCB (PDF 84 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: comments from website consultation (PDF 173 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: appraisal consultation document

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: appraisal consultation document information

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: evaluation report

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: assessment report

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: overview (PDF 230 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation (PDF 1.55 MB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: addendum to the Assessment Report (PDF 407 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: correction to the Addendum Report (PDF 18 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: consultee and commentator comments on the assessment report

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Abbott (PDF 324 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Arthritis and Musculoskeletal Alliance (PDF 38 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Bristol-Myers Squibb (PDF 309 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - British Society For Rheumatology (PDF 610 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Department of Health (PDF 28 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - National Rheumatoid Arthritis Society (PDF 741 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - NHS Quality Improvement Scotland (PDF 47 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Roche Products (PDF 30 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Royal College of Nursing (PDF 24 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Royal College of Physicians (PDF 29 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Schering-Plough (PDF 219 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - UCB Pharma (PDF 67 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: consultee and commentator comments on the assessment report - Wyeth (PDF 36 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: non-manufacturer submissions

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: non-manufacturer submission - Arthritis and Musculoskeletal Alliance (PDF 25 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: non-manufacturer submission - British Health Professionals in Rheumatology (PDF 38 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: non-manufacturer submission - British Society For Rheumatology (PDF 610 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: non-manufacturer submission - National Rheumatoid Arthritis Society (PDF 102 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: non-manufacturer submission - Royal College of Nursing (PDF 312 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: non-manufacturer submission - Royal College of Physicians (PDF 27 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: manufacturer submissions

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: manufacturer submission - Abbott (PDF 23 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: manufacturer submission - Bristol-Myers Squibb (PDF 73 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: manufacturer submission - Roche (PDF 60 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: manufacturer submission - Schering-Plough (PDF 180 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: manufacturer submission - Wyeth (PDF 50 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor: expert written personal statements

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: expert written personal statements - McKenna (PDF 52 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: expert written personal statements - Deighton (PDF 14 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: expert written personal statements - Bosworth (PDF 14 KB)

Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor ACD: expert written personal statements - Burke (PDF 56 KB)

Drugs for the treatment of rheumatoid arthritis (after the failure of TNF inhibitor): assessment report (PDF 1.65 MB)

Drugs for the treatment of rheumatoid arthritis (after the failure of TNF inhibitor): final scope (PDF 37 KB)

Drugs for the treatment of rheumatoid arthritis (after the failure of TNF inhibitor): final matrix of consultees and commentators (PDF 38 KB)

Drugs for the treatment of rheumatoid arthritis (after the failure of TNF inhibitor): comments on the draft scope and provisional matrix (PDF 72 KB)

Drugs for the treatment of rheumatoid arthritis (after the failure of a TNF inhibitor): draft scope (PDF 38 KB)

Drugs for the treatment of rheumatoid arthritis (after the failure of a TNF inhibitor): provisional matrix of consultees (PDF 39 KB)